Applications
PPG-Based COVID-19 Monitoring and Long COVID Assessment
PPG wearables emerged as critical COVID-19 monitoring tools for detecting silent hypoxia (SpO2 drops without dyspnea symptoms), tracking recovery HRV trajectories, and identifying autonomic dysfunction in long COVID patients. Continuous SpO2 monitoring identified early clinical deterioration up to 6 hours before clinical recognition in observational studies.
How it works
Schematic summary of this guide. Waveforms are illustrative, not measured data.
The COVID-19 pandemic created a massive clinical demand for continuous remote SpO2 monitoring in quarantined patients. PPG pulse oximetry became a front-line home monitoring tool after studies showed that many COVID-19 patients develop "happy hypoxia" — profound oxygen desaturation (SpO2 < 90%) in the absence of dyspnea, leading to dangerously delayed care-seeking. Multiple health systems implemented PPG oximetry-based "hospital at home" programs during peak pandemic periods, with the UK NHS Pulse Oximetry at Home program enrolling >47,000 patients.
However, the pandemic also highlighted critical equity issues in pulse oximetry accuracy. Multiple studies (Sjoding et al., NEJM 2020, doi:10.1056/NEJMc2029240; Valbuena et al., BMJ 2022, doi:10.1136/bmj-2021-069775) found disparities in occult hypoxemia associated with recorded race, but their results do not support one universal 3–4% correction for all devices or people with darker pigmentation. The FDA issued a Safety Communication in 2021. In January 2025 it published draft guidance proposing expanded and more objective validation across skin pigmentation for pulse oximeters intended for medical purposes; the draft recommendations are non-binding until finalized.
Autonomic dysregulation such as POTS is reported in some people with long COVID, and HRV from PPG is being studied as a way to track it.
Frequently Asked Questions
How should SpO2 readings be interpreted for COVID-19 home monitoring?
Sustained readings below 94% on FDA-cleared devices warrant urgent medical evaluation. Clinical decisions should account for known accuracy limitations, including more occult hypoxemia in Black patients reported by Sjoding et al. (2020).
Can wearable PPG predict COVID-19 illness before symptom onset?
Research studies have reported resting heart rate and HRV changes around symptom onset, but wearables are not validated for diagnosing COVID-19; use a test.
What is silent hypoxia and why does it matter for COVID-19?
Silent hypoxia is severe oxygen desaturation (SpO2 < 90%) without respiratory distress symptoms. COVID-19 caused a distinctive 'happy hypoxia' syndrome where compensatory mechanisms masked breathlessness despite critical hypoxemia, causing patients to delay seeking care. PPG monitoring enables early detection before clinical decompensation.